Skip to content

A pilot study on combination of siddha formulation(Seenthil chooranam and Serankottai Nei) in the treatment of Rheumatoid Arthritis

A pilot study on combination of siddha formulation in the treatment of Vali Azhal Keel Vayu Rheumatoid Arthritis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/03/008100
Enrollment
20
Registered
2017-03-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Perons affected with Rheumatoid Arthritis Health Condition 2: M069- Rheumatoid arthritis, unspecified

Interventions

Intervention1: Seenthil chooranam: 2g twice daily with lukewarm water for 48 days Intervention2: Serankottai Nei: 10 drops with milk twice daily for 48 days

Sponsors

National Institute of Siddha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects suffering from arthritis of two or more joints 3.Morning stiffness. 4.Swelling especially in the inter-phalangeal joint. 5.Patients willing for admission and stay in IPD or willing to attend OPD 6.Patient willing to undergo Radiological investigation and for laboratory investigation. 7.Patient willing to sign the informed consent stating that he/she will consciously stick to the treatment during 48 days and the patients can opt out of the trial of his/her own conscious discretion.

Exclusion criteria

Exclusion criteria: 1. Subjects with degenerative joint disease or other joint disease such as osteoarthritis,Gouty arthritis,psoriatic arthritis. 2.Subjects with severe disabiling arthritis and/ or bedridden. 3.Women who are pregnant,lactating. 4.Any other serious systemic illness such as diabetic,hypertensive,cardiac disorder,renal and hepatic disorder. 5.Those who unwilling to come for regular follow-up for the entire duration of he study.

Design outcomes

Primary

MeasureTime frame
Remission of this disease will monitored by Disease activity score of 28 joints(DAS28).Timepoint: 48 days

Secondary

MeasureTime frame
Other clinical signs and symptoms will be reducedTimepoint: 48 days

Countries

India

Contacts

Public ContactDr S Sivakumar

National Institute of Siddha

svisu11@gmail.com9962542755

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026